Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether PXT3003 is effective and safe in the
treatment of Charcot-Marie-Tooth disease - Type 1 A (CMT1A). This double-blind study will
assess in parallel groups 2 doses of PXT3003 compared to Placebo in CMT1A patients treated
for 15 months.